Status | In progress |
Technology type | Medicine |
Decision | Selected |
Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
Process | Cost Comparison Standard |
ID number | 6306 |
Project Team
Project lead | Leena Issa |
Email enquiries
- If you have any queries please email TATeam7@nice.org.uk
External Assessment Group | Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
Companies sponsors | Boehringer Ingelheim (tenecteplase) |
Others | Department of Health and Social Care |
NHS England | |
Patient carer groups | None |
Professional groups | Association of British Neurologists |
British and Irish Association of Stroke Physicians | |
Royal College of Physicians | |
Associated public health groups | None |
Comparator companies | Boehringer Ingelheim (alteplase) (confidentiality agreement signed, participating) |
General commentators | All Wales Therapeutics and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Relevant research groups | None |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
13 February 2024 | Invitation to participate |
14 September 2023 - 12 October 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6306 |
03 August 2023 | In progress. DHSC referral received |
07 June 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual